ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

NRAS Inhibitor RLY-8161

Its studies are mostly in Colorectal Neoplasms, led by Relay Therapeutics.

Furthest: phase 2, since Apr 28, 20261 company-led study, 1 open or runningNext primary completion: May 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Relay Therapeutics11 open or runningphase 2since Apr 28, 2026Apr 28, 2026May 31, 2029phase 2 · NCT07584226

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2026First study: phase 2 study in Advanced NRAS-Mutant MelanomaFirst studyNCT07584226 · 180 planned · United States

Ahead

  1. May 31, 2029Primary completion: phase 2 study in Advanced NRAS-Mutant MelanomaNCT07584226

TargetBeta

NRAS →read by rule
“An orally bioavailable inhibitor of the RAS isoform NRAS, ”NCIt, by rule

Other programs on NRAS

ProgramCompanyFurthest phaseStudies
daraxonrasibruleRevolution Medicinesphase 310
RAS Inhibitor AN9025ruleadlai-nortye-biopharma-co-ltdphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07584226Advanced NRAS-Mutant Melanoma · United States2RecruitingMay 31, 2029180

How it is read

Names in the registry

  • “RLY-8161”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.